SOURCE: Elsevier Business Intelligence

Windhover's Therapeutic Area Partnerships

October 13, 2009 11:25 ET

Windhover Brings Roche, Genentech Executives Together to Talk Business Development

NORWALK, CT--(Marketwire - October 13, 2009) - Elsevier Business Intelligence and Windhover Conferences have announced a major addition to the lineup for their upcoming Therapeutic Area Partnerships event, Nov. 17-19 in Boston, MA. In Roche and Genentech: Understanding Their Collaborative Business Development Model, the two executives who designed and implemented the radical new collaborative business model will share exactly how they make this relationship work and the outlook for the business model in the future.

Mary Graves, Executive Director, Roche Pharma Partnering, and Suzy Jones, Senior Director of Business Development, Genentech Partnering, will outline Roche's strategy for retaining Genentech's business development team despite taking the company private. The executives will discuss a variety of strategies, including:

--  Early stage, late stage and TAs, and who does what deal
--  Who to talk to about partnering based on asset stage and therapeutic
    area
--  Strategic priorities in the merged company
--  Commercializing licensed products after the merger
    

Therapeutic Area Partnerships will also feature its popular Top 10 Projects to Watch, including a Top 10 in each of four therapeutic areas: cardiovascular/metabolic, oncology, neuroscience and inflammatory/autoimmune. According to Roger Longman, Managing Director, Pharma, of Elsevier Business Intelligence, many companies previously featured on the Top 10 list have gone on to negotiate major deals.

The complete list of all projects to date (in random order) is available at www.windhover.com/taprojects. Each project has been hand-selected by Windhover's elite selection panel to ensure a high-quality slate of presenters.

Companies will present the product's target and first indication(s); other compounds addressing the same target; the relative advantage of the compound; the clinical results to date and general clinical plan for the future; IP on the compound or target; and any partnerships the company currently holds on the compound. Registered attendees have access to pre-conference access to a database that includes detailed technical, non-confidential information on projects available for partnering (pre-clinical and clinical stage).

Industry analysts will open each Top 10 session with therapy area-specific discussions on Matchmaking in Drug Partnering: Identifying the Right Drugs and the Right Partners

A major partnering event

Therapeutic Area Partnerships is the industry's most targeted and efficient partnering meeting for life science companies seeking partnerships in the top therapeutic areas. Decision-makers (business development and R&D) focusing on these therapeutic categories can meet to develop strategic alliances between their companies. Also, attendees enjoy the personal and interactive setting that combines company presentations, 1:1 meetings and networking functions.

Online registration for Therapeutic Area Partnerships is available at www.tapartnerships.com.

Leading industry executives will discuss timely issues at Therapeutic Area Partnerships, including Therapeutic Area Partnering: Predicting Pharma Strategies in a Post Primary Care World with Elsevier Business Intelligence's Roger Longman; Who Is your Best Partner?: How Deals Differ in Various Therapeutic Areas; and Deal Structures that Allow Large and Small Companies to Share Risk.

Top industry executives and strategists to speak at Therapeutic Area Partnerships include Dr. Carlo Russo, SVP, Biopharmaceutical Development, GlaxoSmithKline; Peter Wirth, Executive Vice President, Legal and Corporate Development, Genzyme Corp.; and Dr. Jeremy Levin, Senior Vice President, Strategic Transactions, Bristol-Myers Squibb. Additional speakers are available on the website.

Therapeutic Area Partnerships will also offer several in-depth workshops.

Global Sponsor for Therapeutic Area Partnerships is Campbell Alliance; Gold Industry Sponsors are Astellas, Merck & Co. and Sanofi Aventis; and Association Sponsor is the Licensing Executives Society. Regional Supporting Organization is BioteCanada; Neuroscience Advisor is NI Research; Inflammation Advisor is Healogix; Oncology Advisor is Campbell Alliance; and Cardiovascular/Metabolic Advisor is DefinedHealth. Media Partner is Pharmalicensing.com, and Major Supporting Publications are IN VIVO: The Business & Medicine Report;™ Start-Up: Emerging Medical Ventures;™ and "The Pink Sheet."

To register, contact Pat Cardone at (203) 838-4401 ext. 124 or pccardone@windhover.com; or register on the Therapeutic Area Partnerships 2009 website at www.tapartnerships.com.

About Windhover Conferences and Elsevier Business Intelligence

Windhover Conferences is an Elsevier Business Intelligence company, the leading provider of business intelligence and analysis to senior executives in the medical device, pharmaceutical, and biotechnology industries. Publishers of IN VIVO: The Business & Medicine Report, Start-Up: Emerging Medical Ventures, The RPM Report: Regulation • Policy • Market Access, Medtech Insight, The Pink Sheet and The Pink Sheet Daily, Elsevier and Windhover also host a variety of industry meetings and webinars in both medical device and pharma/biotech, and produce a wide array of market research reports. For more on the companies' products and services, please visit www.ElsevierBI.com.

Contact Information